
## UCB Interim Report for the first three months of 2015:

# Strong growth, at constant and actual exchange rates, driven by core medicines - and good progress in R&D

- Revenue up 19%* to € 895 million, +11% at constant currencies.
- Cimzia®, Vimpat® and Neupro® combined net sales of € 433 million, +36% or +20% at constant currencies. Keppra® net sales of € 190 million (+14%; +4%)
- R&D update: Phase 3 for Vimpat® in PGTCS has started
- Financial outlook 2015 confirmed

**Brussels (Belgium), 30 April 2015 – 7:00 (CET) – regulated information** –
"UCB had a good start into the year serving more and more patients living with neurological or immunological diseases. At the same time, Cimzia®, Vimpat® and Neupro®, show strong growth at both, constant and actual exchange rates. We are also making good progress with our early and late-stage clinical development activities," said Jean-Christophe Tellier, CEO UCB.

Revenue reported for the first three months of 2015 are € 895 million, a plus of 19%* or 11% at constant exchange rates (CER) driven by the strong growth of Cimzia®, Vimpat® and Neupro® with combined net sales of € 433 million, while Keppra® reached € 190 million – the four medicines together represent 70% of UCB's revenue in the first quarter 2015.

For Cimzia® (*certolizumab pegol*) for inflammatory TNF mediated diseases, UCB reports net sales of € 227 million, +42% (+24% CER), supported by continuously broadened access to patients with active psoriatic arthritis or severe active axial spondyloarthritis. Cimzia® net sales in Japan are reflecting the order pattern of our partner while the in-market growth was positive (+36%).

| € million | 3m 2015 | 3m 2014 | Actual | CER |
|---|---|---|---|---|
| U.S. | 146 | 99 | 47% | 21% |
| Europe | 66 | 49 | 34% | 32% |
| Japan | 0.1 | 3 | -98% | -98% |
| Emerging markets[1] | 2 | 1 | 66% | 70% |
| Rest of the World | 12 | 7 | 69% | 63% |
| Total Cimzia® | 227 | 160 | 42% | 24% |

[1] Emerging markets - BRICMT: Brazil, Russia, India, China, Mexico, Turkey
* 2014 revenue have been restated reflecting the treatment of Kremers Urban as discontinued operation.
All figures are unaudited

Vimpat® (*lacosamide*) for epilepsy reached net sales of € 146 million, an increase of 39% (+20% CER). In the U.S. and since September 2014, Vimpat® is also available for monotherapy treatment of partial onset seizures.

| € million | 3m 2015 | 3m 2014 | Actual | CER |
|---|---|---|---|---|
| U.S. | 109 | 76 | 44% | 18% |
| Europe | 31 | 25 | 23% | 22% |
| Emerging markets[2] | 1 | 1 | 19% | 18% |
| Rest of the World | 5 | 4 | 44% | 56% |
| Total Vimpat® | 146 | 105 | 39% | 20% |

For Neupro® (*rotigotine*), the patch for Parkinson's disease and restless legs syndrome, net sales were € 60 million, +14% (+8% CER).

| € million | 3m 2015 | 3m 2014 | Actual | CER |
|---|---|---|---|---|
| U.S. | 16 | 14 | 14% | -6% |
| Europe | 36 | 32 | 11% | 10% |
| Japan | 6 | 5 | 27% | 27% |
| Emerging markets[1] | 0.5 | 0.3 | 56% | 51% |
| Rest of the World | 2 | 1 | 68% | 59% |
| Total Neupro® | 60 | 52 | 14% | 8% |

Keppra® (*levetiracetam*) for epilepsy net sales reached € 190 million, up by 14% (+4% CER). In the US, Keppra® net sales benefited from stocking effects which are not expected to reoccur in the next quarters.

| € million | 3m 2015 | 3m 2014 | Actual | CER |
|---|---|---|---|---|
| U.S. | 63 | 44 | 41% | 16% |
| Europe | 64 | 72 | -11% | -12% |
| Japan | 25 | 21 | 21% | 15% |
| Emerging markets[1] | 26 | 19 | 40% | 27% |
| Rest of the World | 12 | 11 | 11% | -3% |
| Total Keppra® | 190 | 167 | 14% | 4% |

## Financial outlook 2015 confirmed:

UCB expects the continued growth of Cimzia®, Vimpat®, Neupro® to drive overall company growth. 2015 revenue should reach approximately € 3.55-3.65 billion; recurring EBITDA should increase to approximately € 710-740 million. Core earnings per share (EPS) are expected in the range of € 1.90-2.05 based on an average of 193.7 million shares outstanding.

## R&D update

The Phase 3 program for Vimpat® in primary generalized tonic-clonic seizures (PGTCS) has started in April 2015. First headline results are expected in 2019.

In March 2015 E Keppra® was filed with the Japanese regulatory authorities as adjunctive therapy for PGTCS. In February, the Japanese regulatory authorities approved E Keppra® as monotherapy in the treatment of partial-onset seizures in people living with epilepsy aged four years and above.

[1] Emerging markets - BRICMT: Brazil, Russia, India, China, Mexico, Turkey
All figures are unaudited

In February 2015, UCB announced positive Phase 3 top-line results with Neupro® in the treatment of patients in China with Parkinson's disease. Regulatory submission is planned in 2015.

In January 2015, *brivaracetam* as adjunctive therapy for the treatment of partial-onset seizures in patients from 16 years of age with epilepsy was filed with the U.S. and EU regulatory authorities.

In January 2015, Neuropore and UCB entered into world-wide collaboration in the development of a small molecule disease modifying treatment option for people living with Parkinson's disease. A Phase 1 study is scheduled to start in 2015.

Also in January 2015, for Cimzia® (*certolizumab pegol*), Dermira and UCB announced the start of the Phase 3 program in psoriasis. Top-line data from this program are expected in 2017.

All other clinical development programs are continuing as planned.

## For further information

**Investor Relations**

Antje Witte, Investor Relations, UCB

T +32.2.559.94.14, antje.witte@ucb.com

Isabelle Ghellynck, Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

**Corporate Communications**

France Nivelle, Global Communications, UCB

T +32.2.559.9178, france.nivelle@ucb.com

Laurent Schots, Media Relations, UCB
T+32.2.559.92.64, laurent.schots@ucb.com

### About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

### Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships,

[1] Emerging markets - BRICMT: Brazil, Russia, India, China, Mexico, Turkey
All figures are unaudited

joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.



[1] Emerging markets - BRICMT: Brazil, Russia, India, China, Mexico, Turkey
All figures are unaudited